Effect of amlodipine and hormone replacement therapy on blood
pressure and bone markers in menopause

Zacharieva, Sabina; Shigarminova, R.; Nachev, E.; Kamenov, Zdravko; Atanassova, Iliana; Orbetzova, Maria; Stoynev, Alexander; Doncheva, N.; Am, Borissova

doi:10.1358/mf.2003.25.3.769642

Cited by 15 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A decrease was seen in plasma calcitonin levels in patients treated with nifedipine and nisoldipine [50]. Amlodipine was assessed in an 8-week study that showed no changes in bone remodeling markers [51].…”

Section: Calcium Channel Blockersmentioning

confidence: 99%

Effect of the Antihypertensive Treatment on the Bone Mineral Density and Osteoporotic Fracture

Pérez‐Castrillón¹,

Justo²,

Sanz-Cantalapiedra³

et al. 2005

CHYR

View full text Add to dashboard Cite

The financial and social cost of hypertension and osteoporosis, clinically silent diseases, are determined by the consequences, such as a vascular disease and fractures. The relationship between these illnesses has not been clearly established, although many alterations in extracellular metabolism of calcium, which could determine the level of bone mineral density (BMD) in these patients, have been associated to hypertension. Despite these alterations, the lack of studies relating these two important diseases is surprising, and hypertension is not identified as a risk factor for osteoporosis.Interestingly, there is a lack of information of the long-term effects of antihypertensive treatment on bone mineral density, although 50 % of the hypertensive population is made up of postmenopausal women. Most studies analyzed the effects of thiazides and, to a lesser degree, the effects of calcium antagonist.The purpose of this review is evaluate the effect of the antihypertensive therapeutic group (diuretics, β-blockers, calcium antagonists, angiotensin converting enzyme) on the bone mineral density (BMD) and osteoporotic fracture.

show abstract

Section: Calcium Channel Blockersmentioning

confidence: 99%

Effect of the Antihypertensive Treatment on the Bone Mineral Density and Osteoporotic Fracture

Pérez‐Castrillón¹,

Justo²,

Sanz-Cantalapiedra³

et al. 2005

CHYR

View full text Add to dashboard Cite

show abstract

“…[6][7][8][9][10] However, meta-analysis of observational studies on the effects of antihypertensive drugs on fracture outcomes demonstrated no significant association between fractures and calcium channel blockers (CCBs). [11][12][13] CCBs are divided into several subtypes, and non-dihydropyridinetype CCBs, but not dihydropyridine-type CCBs, are reported to reduce the risk of bone fractures through the inhibition of hyperparathyroidism-induced calcium uptake into osteoblasts and an elevation of intracellular calcium in osteoclasts. 14,15 Cilnidipine, a new type of CCB that blocks the N-type calcium channel and the L-type calcium channel, is therefore thought to affect bone metabolism, possibly through the inhibition of both the sympathetic nervous system and the voltage-dependent calcium channel.…”

Section: Introductionmentioning

confidence: 99%

Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel

et al. 2011

View full text Add to dashboard Cite

Both osteoporosis and high blood pressure are major diseases in aging populations. Recent studies demonstrated that some antihypertensive drugs reduced the risk of bone fracture in elderly patients. Although calcium channel blockers (CCB) are widely used as first-line antihypertensive agents, there is no evidence that they prevent osteoporosis. In this study, we investigated the effects of two types of CCB on bone metabolism: cilnidipine (L-/N-type CCB), which suppresses norepinephrine release from the sympathetic nerve, and amlodipine (L-type CCB). In ovariectomized female spontaneous hypertensive rats, administration of cilnidipine, but not amlodipine, resulted in a significant increase in the ratio of alkaline phosphatase to tartrate-resistant acid phosphatase (TRAP) and a decrease in the number of osteoclasts, as assessed by TRAP staining in the proximal tibia. Bone mineral density, moreover, was significantly higher in the cilnidipine group as compared with the amlodipine group and was associated with a significant decrease in a urinary collagen degradation product (deoxypyridinoline). The degree of prevention of osteoporosis by cilnidipine was similar to that of carvedilol (a b-blocker) because b-blockers reduce fracture risks though the inhibition of osteoclast activation. Interestingly, these effects cannot be attributed to the reduction of blood pressure because all three drugs significantly decreased blood pressure. In contrast, both cilnidipine and carvedilol, but not amlodipine, significantly decreased heart rate, indicating that both cilnidipine and carvedilol suppressed sympathetic nervous activity. Overall, our present data showed that cilnidipine (L-/N-type CCB) ameliorated osteoporosis in ovariectomized hypertensive rats. These pleiotropic effects of antihypertensive drugs such as cilnidipine and carvedilol might provide additional benefits in the treatment of hypertensive postmenopausal women.

show abstract

“…In regard to CCB, there is no evidence of their value for the treatment of osteoporosis associated with hypertension. Although a few clinical and basic reports suggest beneficial effects of CCB, a meta‐analysis of observational studies showed no significant relationship between fracture risk and the use of CCB . ACEI and ARB are considered to be most useful against reduction of BMD in hypertensive patients.…”

Section: Discussionmentioning

confidence: 99%

Effect of angiotensin II receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome

Aoki

Kawahata

Sotobayashi

et al. 2014

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

Effect of amlodipine and hormone replacement therapy on blood pressure and bone markers in menopause

Cited by 15 publications

References 0 publications

Effect of the Antihypertensive Treatment on the Bone Mineral Density and Osteoporotic Fracture

Effect of the Antihypertensive Treatment on the Bone Mineral Density and Osteoporotic Fracture

Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel

Effect of angiotensin II receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome

Contact Info

Product

Resources

About